Log in to search using one of your social media accounts:

 

Albireo to initiate A4250 ’s Phase III clinical programme to treat PFIC
Albireo Pharma is planning to initiate a Phase III clinical programme of its product candidate A4250 in the second half of this year for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC). (Source: Drug Development Technology)
Source: Drug Development Technology - May 21, 2017 Category: Pharmaceuticals Source Type: news

Discovery provides insight into life-threatening respiratory distress in newborns
St. Jude Children’s Research Hospital scientists advance understanding of intrahepatic cholestasis of pregnancy, a liver disorder that leaves infants born to affected mothers at risk for severe respiratory distress (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 29, 2015 Category: Science Source Type: news

Intrahepatic cholestasis of pregnancy linked with liver cancer
(University of Gothenburg) In a new study of more than 125,000 pregnant women in Sweden, researchers at the Sahlgrenska Academy found that the risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is higher in women with intrahepatic cholestasis of pregnancy than in women without this condition. Their results are published in the Journal of Hepatology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 12, 2015 Category: Cancer & Oncology Source Type: news

Research links intrahepatic cholestasis of pregnancy with liver cancer and other diseases later in life
(Elsevier Health Sciences) In a new study of more than 125,000 pregnant women in Sweden, researchers found that the risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is higher in women with intrahepatic cholestasis of pregnancy than in women without this condition. Their results are published in the Journal of Hepatology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2015 Category: Cancer & Oncology Source Type: news

Lumena doses first patients in Phase II trial of LUM001
US-based Lumena Pharmaceuticals has started dosing the first patient in the INDIGO Phase II clinical trial of its lead drug candidate, LUM001, in children with progressive familial intrahepatic cholestasis (PFIC). (Source: Drug Development Technology)
Source: Drug Development Technology - May 12, 2014 Category: Pharmaceuticals Source Type: news

Postnatal Obesity Triggered During Pregnancy
During pregnancy, the health of the mother and the intrauterine environment can have dramatic and lasting effects on the child. Intrahepatic cholestasis of pregnancy (ICP) is a liver disease that affects 0.5-2% of pregnant women and is characterized by increased bile acid levels in the maternal serum. In this issue of the Journal of Clinical Investigation, Catherine Williamson and colleagues at Imperial College London studied the long term impact of ICP in a cohort of Finnish families... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 26, 2013 Category: Consumer Health News Tags: Pregnancy / Obstetrics Source Type: news

Stillbirth And Liver Problems: New Treatment Target On The Horizon
Obstetric cholestasis (OC) is a liver condition that occurs during pregnancy in women. It affects about one in 140 pregnancies in the UK, and can result in stillbirth.1,2 Abnormally high levels of substances in the body linked with pregnancy hormones can contribute to the development of OC, by reducing the body's ability to remove bile from the liver. This results in a build up of toxic bile acids in the bloodstream, causing severe itching especially on the hands and feet, from around week 28 of pregnancy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 5, 2013 Category: Consumer Health News Tags: Pregnancy / Obstetrics Source Type: news